| Literature DB >> 27379023 |
Hanifa Ziane1, Vera Manageiro2, Eugénia Ferreira3, Inês B Moura3, Soumia Bektache1, Mohamed Tazir1, Manuela Caniça3.
Abstract
In Algeria, few data is available concerning the distribution of pneumococcal serotypes and respective antibiotic resistance for the current pre-vaccination period, which is a public health concern. We identified the most frequent Streptococcus pneumoniae serogroup/types implicated in invasive pneumococcal disease (IPD; n = 80) and carriage (n = 138) in Algerian children younger than 5 years old. Serogroup/types of 78 IPD isolates were identified by capsular typing using a sequential multiplex PCR. Overall, serotypes 14, 19F, 6B, 23F, 18C, 1, 5, 7F, 19A, and 3 (55% of PCV7 serotypes, 71.3% of PCV10, and 90% of PCV13) were identified. Additionally, 7.5% of the non-vaccine serotypes 6C, 9N/L, 20, 24F, 35B, and 35F, were observed. In the case of S. pneumoniae asymptomatic children carriers, the most common serogroup/types were 6B, 14, 19F, 23F, 4, 9V/A, 1, 19A, 6A, and 3 (42.7% of PCV7 serotypes, 44.2% of PCV10, and 58% of PCV13). For 6.1% of the cases co-colonization was detected. Serotypes 14, 1, 5, and 19A were more implicated in IPD (p < 0.01), whereas serotype 6A was exclusively isolated from carriers (p < 0.01). Deaths associated with IPD were related to serotypes 19A, 14, 18C, and one non-typeable isolate. Among IPD related to vaccine serotypes, the rates of penicillin non-susceptible isolates were higher in no meningitis cases (80%) than in meningitis (66.7%), with serotypes 14, 19A, 19F, and 23F presenting the highest MIC levels (>2μg/ml). Resistance to cefotaxime was higher in isolates from meningitis (40.5%); however, resistance to erythromycin and co-trimoxazole (>40%) was more pronounced in no-meningeal forms. Overall, our results showed that PCV13 conjugate vaccine would cover up to 90% of the circulating isolates associated with IPD in Algeria, highlighting the importance of monitoring the frequency of S. pneumoniae serogroups/types during pre- and post-vaccination periods.Entities:
Keywords: Algeria; antibiotic susceptibility; children; invasive disease; pneumococcal carriage; pneumococci serotype; vaccine
Year: 2016 PMID: 27379023 PMCID: PMC4905970 DOI: 10.3389/fmicb.2016.00803
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Multiplex PCR scheme used in capsular typing of .
Figure 2Serogroup/types distribution and age groups in children under 5 years old according to clinical presentations of invasive pneumococcal disease (IPD) episodes. Abdominal infections, S. pneumoniae was isolated from ascitic and peritoneal fluids; NT, non-typeable.
.
| 4 | 1 | 1 | 2 | 4 | 4 | 0.161 | ||||
| 6 B | 4 | 1 | 1 | 6 | 12 | 2 | 2 | 16 | 22 | 0.245 |
| 9V/A | 1 | 2 | 3 | 3 | 0.256 | |||||
| 14 | 13 | 6 | 7 | 26 | 4 | 4 | 5 | 13 | 39 | <0.01 |
| 18 C | 1 | 1 | 1 | 0.364 | ||||||
| 19 F | 2 | 4 | 2 | 8 | 6 | 5 | 1 | 12 | 20 | 0.449 |
| 23 F | 1 | 2 | 3 | 8 | 1 | 2 | 11 | 14 | 0.182 | |
| Subtotal | 20 | 12 | 12 | 44 | 31 | 14 | 14 | 59 | 103 | 0.045 |
| 1 | 4 | 1 | 1 | 6 | 2 | 2 | 8 | 0.028 | ||
| 5 | 5 | 1 | 6 | 6 | <0.01 | |||||
| 7 F | 1 | 1 | 1 | 0.364 | ||||||
| Subtotal | 10 | 2 | 1 | 13 | 2 | 2 | 15 | <0.01 | ||
| 3 | 3 | 3 | 1 | 1 | 4 | 0.138 | ||||
| 6A | 11 | 1 | 1 | 13 | 13 | <0.01 | ||||
| 19 A | 6 | 4 | 2 | 12 | 5 | 5 | 17 | <0.01 | ||
| Subtotal | 9 | 4 | 2 | 15 | 16 | 1 | 2 | 19 | 34 | 0.203 |
| 6 C | 1 | 1 | 1 | 1 | 2 | 3 | 0.700 | |||
| 8 | 1 | 1 | 1 | 0.636 | ||||||
| 9 N/L | 1 | 1 | 1 | 0.364 | ||||||
| 10A | 1 | 1 | 1 | 0.636 | ||||||
| 11A/D | 3 | 3 | 3 | 0.256 | ||||||
| 15 | 1 | 1 | 1 | 0.636 | ||||||
| 15 A/F | 3 | 1 | 2 | 6 | 6 | 0.064 | ||||
| 15B/C | 5 | 5 | 5 | 0.116 | ||||||
| 16F | 1 | 1 | 1 | 0.636 | ||||||
| 17F | 1 | 1 | 1 | 0.636 | ||||||
| 20 | 1 | 1 | 1 | 1 | 2 | 0.700 | ||||
| 23A | 1 | 1 | 2 | 2 | 0.404 | |||||
| 23B | 3 | 1 | 4 | 4 | 0.161 | |||||
| 24 F | 1 | 1 | 1 | 1 | 2 | 3 | 0.700 | |||
| 33F/A/37 | 1 | 1 | 1 | 0.636 | ||||||
| 34 | 4 | 1 | 5 | 5 | 0.116 | |||||
| 35 B | 1 | 1 | 3 | 1 | 4 | 5 | 0.401 | |||
| 35 F | 1 | 1 | 1 | 0.364 | ||||||
| Subtotal | 4 | 1 | 1 | 6 | 29 | 2 | 9 | 40 | 46 | <0.01 |
| Total Typeable | 43 | 19 | 16 | 78 | 78 | 17 | 25 | 120 | 198 | <0.01 |
| Non typeable | 1 | 1 | 2 | 13 | 3 | 2 | 18 | 20 | <0.01 | |
| Global Total | 44 | 20 | 16 | 80 | 91 | 20 | 27 | 138 | 218 | |
One-tail P ≤ 0.05 were considered to be statistically significant.
Four isolates were serotyped by Multiplex PCR and one was serotyped by Quellung reaction.
Isolates serotyped only by Quellung reaction.
Three Multiplex PCR non-typeable isolates were serotyped only by Quellung reaction (serotypes 19Ab, 15c, and 20c).
Figure 3Distribution of serogroup/types and pneumococcal conjugate vaccine (PCV) coverage for invasive pneumococcal disease (IPD) (. NT, non-typeable.
Figure 4Rate of serogroup/type cumulative coverage (C %) in each conjugate vaccine (PCV7, PCV10, PCV13) for . NT, non-typeable.
Antibiotic susceptibility of 72 isolates of vaccine serotypes.
| Meningitis | 33.3 | – | 66.7 | 66.7 | 39 | 0.06 | 0.12 |
| No meningitis | 88.0 | 8.0 | 4.0 | 12.0 | 25 | 2 | 8 |
| No meningitis | 20.0 | 32.0 | 48.0 | 80.0 | 25 | 0.06 | 2 |
| No meningitis | 86.4 | 9.1 | 4.5 | 13.6 | 22 | 2 | 8 |
| Meningitis | 59.5 | 40.5 | 0.0 | 40.5 | 37 | 0.5 | 2 |
| No meningitis | 91.7 | 8.3 | 0.0 | 8.3 | 24 | 1 | 4 |
| Meningitis | 56.8 | 37.8 | 5.4 | 43.2 | 37 | 0.12 | 1 |
| Meningitis | 57.5 | 0.0 | 42.5 | 42.5 | 40 | ≥21 | ≤15 |
| No meningitis | 25.9 | 0.0 | 74.1 | 74.1 | 27 | ≥21 | ≤15 |
| Meningitis | 60.0 | 0.0 | 40.0 | 40.0 | 40 | ≥19 | ≤15 |
| No meningitis | 33.3 | 0.0 | 66.7 | 66.7 | 27 | ≥19 | ≤15 |
| Meningitis | 46.2 | 2.6 | 51.2 | 53.8 | 39 | ≥19 | ≤15 |
| No meningitis | 25.0 | 0.0 | 75.0 | 75.0 | 24 | ≥19 | ≤15 |
| Meningitis | 71.8 | 2.6 | 25.6 | 27.2 | 39 | ≥28 | ≤24 |
| No meningitis | 57.7 | 3.8 | 42.3 | 46.2 | 26 | ≥28 | ≤24 |
Includes serogroups/types: 1 (n = 6), 3 (n = 3), 5 (n = 6), 6B (n = 6), 7 (n = 1), 14 (n = 26), 18C (n = 1), 19A (n = 12), 19F (n = 8), and 23F (n = 3).
Susceptibility testing by E-test method (MIC determination), for penicillin, amoxicillin, cefotaxime, and imipenem.
Susceptibility testing by agar disk diffusion method, for erythromycin, clindamycin, co-trimoxazole, tetracycline.
S, Susceptible; I, Intermediate; R, resistant; IR, non-susceptible.